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AbsTrACT
Objective compare efficacy and safety of vonoprazan 
and lansoprazole for secondary prevention of low-dose 
aspirin (lDa)-associated peptic ulcers in a 24-week study 
and long-term extension therapy in separate study.
Design Double-blind, randomised, non-inferiority study; 
single-blind extension study at 104 Japanese sites, 
including 621 patients (439 in extension) with a history 
of peptic ulcers who required long-term lDa therapy. 
randomised (1:1:1, computer generated) patients 
received lansoprazole 15 mg (n=217), vonoprazan 10 mg 
(n=202) or vonoprazan 20 mg (n=202) once daily for 
24 weeks (double blind) and ≤2 years (extension). the 
following measurements were made: 24-week (primary 
outcome; double blind) and 12-week peptic ulcer 
recurrence rate, 24-week gi bleeding rate, cumulative 
incidences of peptic ulcer recurrence and gi bleeding, 
treatment-emergent adverse events, laboratory results, 
serum gastrin and pepsinogen i/ii concentrations.
results the 24-week peptic ulcer recurrence rate 
was 2.8%, 0.5% and 1.5% in the lansoprazole 15 mg, 
vonoprazan 10 mg and vonoprazan 20 mg groups, 
respectively. Vonoprazan was non-inferior (Farrington 
and Manning test: margin 8.7%, significance level 2.5%) 
to lansoprazole. in the post hoc analyses of the extension 
study, peptic ulcer recurrence rates were significantly 
lower with vonoprazan 10 mg (log-rank test, P=0.039), 
but not vonoprazan 20 mg (P=0.260), compared with 
lansoprazole 15 mg. gi bleeding rates were higher with 
lansoprazole compared with two doses of vonoprazan in 
both 24-week study and extension study.
Conclusion Vonoprazan (10 and 20 mg) was as 
effective as lansoprazole (15 mg) in preventing peptic 
ulcer recurrence during lDa therapy, had a similar long 
-term safety profile and was well tolerated.
Trial registration numbers nct01452763; 
nct01456247.
InTrODuCTIOn
Low-dose aspirin (LDA) is commonly used to 
prevent the formation of thrombi in patients 
with ischaemic heart or cerebrovascular diseases. 
Even at low doses, however, aspirin can cause GI 
mucosal injury by inhibiting the biosynthesis of 
intrinsic prostaglandin.1 The discontinuation of 
LDA can increase the risk of cerebral/cardiovascular 
events.2–4 The guideline recommended that LDA be 
continued in patients with a risk factor of those 
events5; other guidelines have made similar sugges-
tions6 7; however, continuing LDA may contribute 
to increasing the chances of rebleeding. Therefore, 
it is clinically important to prevent mucosal injury 
while continuing administration of LDA.
Although proton pump inhibitors (PPIs) are indi-
cated for prevention of gastric or duodenal (peptic) 
ulcer recurrence during LDA administration, some 
patients experience ulcer recurrence,8 9 indicating 
that secondary prevention cannot be completely 
achieved.
Vonoprazan is a novel potassium-competitive 
acid blocker developed by Takeda Pharmaceutical 
Company. Vonoprazan inhibits H+, K+-ATPase in 
gastric parietal cells at the final stage of the acid 
secretory pathway in a K+-competitive and revers-
ible manner.10 11 From a clinical perspective, vono-
prazan has a number of advantages over PPIs. For 
significance of this study
What is already known on this subject?
 ► Due to the increase of cardiovascular diseases 
with the ageing population, the frequency of 
antithrombotic prescriptions, including aspirin, 
is increasing, thereby leading to an elevated 
risk of GI bleeding.
 ► Since temporary cessation of antithrombotics 
increases the risk of mortality, ulcer prevention 
is important during aspirin therapy.
 ► Proton pump inhibitor (PPI) is recommended 
for the prevention of aspirin-related GI adverse 
events (AEs); however, several days are 
necessary to achieve a maximal effect and the 
effect varies depending on the genetic type of 
CYP2C19 genes.
What are the new findings?
 ► Based on the different modes of action of 
vonoprazan compared with conventional PPI 
and its high level antacid effect, vonoprazan 
showed equivalent efficacy compared with 
lansoprazole.
 ► Long-term administration of vonoprazan is well 
tolerated, and 10 mg can be recommended as a 
clinical dose.
How might it impact on clinical practice in the 
foreseeable future?
 ► Vonoprazan is effective for preventing low-dose 
aspirin-related GI AEs with stable effects, and it 
can be considered as a new treatment option.
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example, vonoprazan does not require an acidic environment for 
activation and is acid stable,12 eliminating the need for an enter-
ic-coated formulation. Whereas PPIs require approximately 3–5 
days to achieve maximal inhibition of gastric H+, K+-ATPase,13 
vonoprazan exerts a near-maximum inhibitory effect from the 
first dose and remains effective for 24 hours14 15. Vonoprazan 
provides potent and long-lasting inhibition of gastric acid secre-
tion,10 11 14–16 and its efficacy is therefore expected to be supe-
rior to that of PPIs. In a phase 2 study, vonoprazan (5–40 mg 
once daily) was highly effective and non-inferior to lansopra-
zole 30 mg for the treatment of erosive oesophagitis.17 However, 
there have been no studies comparing the efficacy of vonoprazan 
and PPIs for secondary prevention of LDA-induced ulcers in 
patients with a history of peptic ulcer.
Against this background, a randomised, double-blind, non-in-
feriority phase 3 study with single-blind extension study was 
conducted to investigate the efficacy and safety of vonoprazan 
for prevention of ulcer recurrence in patients with a history of 
peptic ulcer who required long-term LDA therapy for cardiovas-
cular and cerebrovascular protection.
MATerIAls AnD MeTHODs
Design overview
This was a multicenter, randomised, double-blind, double-
dummy, active-controlled, parallel-group, non-inferiority phase 
3 study to compare the efficacy and safety of vonoprazan and 
lansoprazole for the prevention of recurrent peptic ulcers in 
patients who required long-term LDA therapy. The 24-week 
study was conducted between October 2011 and April 2013 at 
104 medical institutions across Japan. The double-blind study 
was followed by a single-blind, parallel-group extension study in 
which consenting patients continued lansoprazole or vonoprazan 
for up to 2 years to evaluate safety and efficacy during long-term 
treatment. The extension study was conducted between March 
2012 and October 2013 at 99 of the original study sites. All 
patients provided written informed consent to participate. 
Participants
Patients were enrolled if they met the following criteria: male or 
female outpatients ≥20 years of age, endoscopically confirmed 
history of peptic ulcer before study start and required long-term 
LDA therapy during the treatment period to prevent the forma-
tion of thrombi related to chronic disease (eg, ischaemic heart or 
cerebrovascular disease).
Patients were excluded if they had: active peptic ulcer or 
bleeding endoscopically confirmed at the screening visit, current 
or past history of aspirin-induced asthma, history of surgery or a 
planned operation affecting gastric acid secretion (eg, upper GI 
tract resection, vagotomy), current or past history of Zollinger-El-
lison syndrome or other gastric acid hypersecretion disorders, clin-
ically significant liver or kidney disorder, including liver tests 
demonstrating aspartate aminotransferase/alanine aminotrans-
ferase values >2.5 times the upper limit of normal (ULN), total 
bilirubin >2.0 times the ULN or creatinine levels >2.0 mg/dL or 
history of malignancy within 5 years before screening.
randomisation and intervention
The 15 mg dose of lansoprazole was selected as in Japan that is 
the only dose which is approved for prevention of LDA-induced 
ulcer recurrence.
Vonoprazan doses of 10 mg and 20 mg were selected based 
on results from a dose-ranging study conducted in Japanese 
patients with erosive oesophagitis where the non-inferiority of 
vonoprazan (at doses of 5, 10, 20 and 40 mg) to lansoprazole 
30 mg was demonstrated.17
Patients were randomly assigned to receive lansoprazole 
15 mg, vonoprazan 10 mg or vonoprazan 20 mg orally once 
daily in a 1:1:1 ratio according to a unique computer-generated 
number sequence for study medication, which was preassigned 
to each study site before the start of treatment. A double-dummy 
method, using matching vonoprazan placebo and lansopra-
zole placebo, was used to maintain blinding and ensure that all 
patients followed the same treatment regimen. Administration of 
LDA at a dose of 81–324 mg/day was to have been started by the 
start of treatment. After termination of the double-blind phase, 
patients were invited to participate in the extension phase during 
which they continued to receive the same study medication in 
single-blind fashion for up to 2 years.
Outcomes and measurements
The primary endpoint of the double-blind study was the rate of 
peptic ulcer recurrence during the 24-week treatment period. 
Ulcer was defined as a mucosal defect with white coat of 3 mm 
or large, measured using endoscopic forceps. The secondary 
endpoints were the rate of peptic ulcer recurrence within 12 
weeks, the rate of occurrence of bleeding in the stomach or 
duodenum (based on modified Forrest classification,18 cases 
classified as I or II were reported as bleedings) and the time to 
peptic ulcer recurrence. Endoscopic findings (for ulcer scarring 
and recurrence) were investigated independently and blindly by 
Central Evaluation Committee consisting of two endoscopists.
Safety was assessed on the basis of treatment-emergent 
adverse events (TEAEs), laboratory test results, ECG findings, 
vital signs, serum gastrin concentrations and serum pepsinogen I 
and II concentrations by RI/PEG method. CYP2C19 gene typing 
were determined by using InvaderPlus (Hologic, Marlborough, 
Massachusetts, USA)
In the extension study, the primary endpoint was the incidence 
of TEAEs. Safety was assessed in the same manner as in the 
double-blind study. The secondary efficacy endpoint was the rate 
of peptic ulcer recurrence. Additional secondary endpoints were 
the rate of occurrence of bleeding in the stomach or duodenum 
and time to peptic ulcer recurrence. The time to bleeding occur-
rence was defined as a post hoc endpoint.
Follow-up procedures
Follow-up endoscopy was scheduled at 12 and 24 weeks of 
treatment. Non-scheduled endoscopy was performed if patients 
were suspected of having symptoms associated with ulcer onset. 
Every 4 weeks, clinical laboratory tests (chemistry, haematology 
and urinalysis) were performed, vital signs were checked, serum 
gastrin and pepsinogen I/II levels were measured and adherence 
checks were conducted. Adverse events were monitored contin-
uously throughout the study.
statistical analysis
A previous phase 3 study evaluating lansoprazole for preven-
tion of ulcer recurrence during LDA therapy in Japanese subjects 
reported that the proportion of patients with recurrent peptic 
ulcer during the 24-week treatment period was 1.8%8; this same 
proportion was assumed for lansoprazole and vonoprazan in the 
current study. Sample size was estimated to ensure a statistical 
power of 90% to detect non-inferiority between each vono-
prazan group and the lansoprazole group using a Farrington and 
Manning non-inferiority test19 with a non-inferiority margin 
of 8.7% (half the value of the treatment difference between 
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lansoprazole 15 mg and gefarnate observed in the above-men-
tioned phase 3 study8). Assuming a dropout rate of 20% after 
randomisation, 210 randomised patients per group (630 total 
patients) were required to detect non-inferiority of vonoprazan 
to lansoprazole. In the extension study, 450 patients (150 per 
group) were planned for evaluation of safety.
Analyses were conducted on the full analysis set (FAS), defined 
as all patients who were randomised and received one or more 
doses of study medication.
For the primary endpoint (proportion of patients with peptic 
ulcer recurrence during the 24-week treatment period), the 
non-inferiority of vonoprazan 10 mg and 20 mg to lansoprazole 
15 mg was tested using the Farrington and Manning test with a 
non-inferiority margin of 8.7% at a significance level of 2.5%. A 
closed testing procedure was used for multiplicity adjustment in 
the tests. Superiority could be claimed if the upper limit of the 
two-sided 95% CI of the difference between groups was greater 
than zero. The other tests were performed at a significance level 
of 5%. In the extension study, the cumulative incidences of peptic 
ulcer recurrence and occurrences of bleeding in the stomach or 
duodenum were calculated by the Kaplan-Meier method.
In the safety analysis set (defined as all patients who received 
study medication), the frequency distribution of TEAEs was 
provided for each treatment group. For continuous variables, 
descriptive statistics were used to summarise observed values 
and changes from baseline by treatment group for each visit. For 
categorical variables, shift tables were provided for each treat-
ment group showing the number of patients in each category at 
baseline and at each post-baseline visit.
Analyses were conducted using SAS V.9.2 software.
role of the funding source
Takeda Pharmaceutical Company Ltd. (the Sponsor) and its 
contractor provided all financial and material support for the 
study design, data collection, data analysis, data interpretation, 
and preparation and review of manuscripts. The Sponsor was 
also responsible for consulting with the authors and members of 
the study group about the study design and study monitoring.
resulTs
study patients
Of 809 patients screened, 621 patients were randomised to 
treatment (figure 1); these patients comprise both the FAS and 
safety analysis set. The remaining 188 patients were excluded 
mainly for failing to meet the inclusion criteria (n=152) or 
voluntary withdrawal (n=24). All randomised patients received 
study medication and 574 patients completed the double-blind 
study. Of the 47 patients who discontinued the study prema-
turely, most were because of adverse events (n=29) or volun-
tary withdrawal (n=12). Among the patients who completed the 
double-blind study, 439 entered the extension study, which was 
originally planned to enrol 140 patients in each arm. Out of 439 
patients, 405 completed treatment. Among the 34 patients who 
discontinued treatment (11, 12 and 11 patients in the lansopra-
zole 15 mg, vonoprazan 10 mg and vonoprazan 20 mg groups, 
respectively), the main reasons were adverse events (n=22) or 
voluntary withdrawal (n=7).
There were no clinically meaningful differences among treat-
ment groups in patient characteristics at baseline (table 1). 
Adherence with study medication was high across all treatment 
groups (>99%). The median duration of exposure was approxi-
mately 52 weeks (overall range 2–684 days (<1 to 98 weeks)) in 
all treatment groups.
efficacy
In the FAS population, the proportion of patients with endo-
scopically confirmed recurrent peptic ulcer during the 24-week 
treatment period (primary endpoint) was higher in the lansopra-
zole 15 mg group (2.8%; 6 of 213 patients) than in the vono-
prazan 10 mg (0.5%; 1 of 197 patients) and vonoprazan 20 mg 
groups (1.5%; 3 of 196 patients). The differences in recurrence 
rate between the lansoprazole 15 mg group and the vonoprazan 
10 mg and 20 mg groups were −2.3% (95% CI −4.743 to 
0.124) and −1.3% (95% CI −4.095 to 1.523), respectively. The 
non-inferiority of vonoprazan to lansoprazole 15 mg was veri-
fied (Farrington and Manning test; P<0.001 for each group). 
The differences in recurrence rates between vonoprazan 10 mg 
and lansoprazole 15 mg (−2.3%) and between vonoprazan 
20 mg and lansoprazole 15 mg (−1.3%) were not statistically 
significant for superiority.
The proportions of patients with recurrent peptic ulcer 
confirmed by endoscopy at 12 weeks (secondary endpoint) were 
0.9%, 0.5% and 0.5% for patients treated with lansoprazole 
15 mg, vonoprazan 10 mg and vonoprazan 20 mg, respectively, 
and the between-group differences were not statistically signif-
icant for superiority. However, the proportion of patients with 
bleeding in the stomach or duodenum during the 24-week treat-
ment period (secondary endpoint) was significantly higher in 
the lansoprazole 15 mg group (2.9%) compared with the vono-
prazan 10 mg (0%) and vonoprazan 20 mg (0%) groups (differ-
ence −2.9% (95% CI −5.135 to −0.607) for each group).
In exploratory subgroup analyses, the incidence of peptic 
ulcer recurrence during 24 weeks of treatment with vonoprazan 
10 mg or 20 mg was lower than or similar to that with lanso-
prazole 15 mg, regardless of patient Helicobacter pylori status, 
CYP2C19 genotype, age, smoking status, alcohol consumption 
status or presence/absence of treatment with other oral anti-
thrombotic drugs (table 2).
In the post hoc analyses of the double-blind study, when the 
incidence of gastric or duodenal bleeding was stratified by the 
presence/absence of treatment with oral antithrombotic drugs 
during the 24-week treatment period, bleeding incidence was 
higher with oral antithrombotic drugs in lansoprazole 15 mg at 
4.4%, but the incidence was 1.7% without oral antithrombotic 
drugs. Bleeding incidence among those received oral antithrom-
botic drugs were 0.0% in both vonoprazan 10 mg and 20 mg 
(difference −4.4% (95%CI −8.702 to −0.187) for each group) 
and the between-group differences were statistically significant 
for superiority (Wald test, P=0.0408). Statistical significance 
between lansoprazole 15 mg and both vonoprazan 10 mg and 
20 mg were observed by Wald test (P=0.0408).
In the post hoc analyses of the extension study, the cumulative 
incidence of peptic ulcer recurrence, as calculated by the Kaplan-
Meier method, was significantly lower with vonoprazan 10 mg 
(log-rank test, p=0.039), but not vonoprazan 20 mg (p=0.260), 
compared with lansoprazole 15 mg. Ulcer recurrences were 
limited to gastric ulcers. The cumulative incidence of bleeding 
in the stomach or duodenum, as calculated by the Kaplan-Meier 
method (post hoc), was significantly lower with both vono-
prazan 10 mg (log-rank test, p=0.018) and vonoprazan 20 mg 
(p=0.019) compared with lansoprazole 15 mg (figure 2A, B).
safety
Across the double-blind and extension studies, the incidences 
of TEAEs, adverse events for which a causal relationship with 
study medication could not be eliminated, and adverse events 
leading to drug discontinuation were similar between treatment 
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groups (table 3). The number of serious adverse events for which 
a causal relationship to study medication could not be eliminated 
was low (1.4% in the lansoprazole 15 mg group, 2.0% in the 
vonoprazan 10 mg and vonoprazan 20 mg groups; table 3). In 
the lansoprazole 15 mg group, there were three such events 
in three patients (one case each of acute pancreatitis, cervical 
adenocarcinoma and acute renal failure). In the vonoprazan 
10 mg group, there were five events in four patients (one case 
each of acute pancreatitis, large intestine polyp, cholelithiasis, 
thrombotic cerebral infarction and diabetic neuropathy). In the 
vonoprazan 20 mg group, there were four events in four patients 
(two cases of gastric cancer and one case each of enterocolitis 
and oral fibroma). One death due to cardiac failure occurred in 
the vonoprazan 10 mg group, but this was considered unrelated 
to study medication.
The most common TEAEs reported in patients (irrespective of 
causal relationship to study medication) occurred at similar rates 
in each group and included nasopharyngitis (approximately 30%) 
and constipation (approximately 7%) (table 3). The incidence of 
diarrhoea was lower in both vonoprazan groups (7.4%–9.4%) 
than in the lansoprazole group (12%) (table 3). Most adverse 
events were classified as mild or moderate in intensity (≥98.5% 
in each group). The incidence of fracture was similar in all treat-
ment groups. There was no report of Clostridium difficile infection 
in either the double-blind or extension study (table 3). GI carci-
nomas were identified in one patient (0.5%) treated with lanso-
prazole, three patients (1.5%) treated with vonoprazan 10 mg and 
six patients (3.0%) treated with vonoprazan 20 mg (table 3). There 
were no cardiovascular events in the 120 patients who concomi-
tantly received clopidogrel and LDA.
No clinically significant changes were observed in vital signs, 
haematology tests, serum chemistry, or urinalysis before and after 
treatment for any group. Serum gastrin levels increased from 
baseline in all groups after 4 weeks of treatment and increased 
moderately thereafter up to 52 weeks of treatment (figure 3). 
Serum gastrin levels were higher with vonoprazan 10 mg and 
Figure 1 Patient disposition in the double-blind and extension studies. (A) 24-Week study. (B) Extension study. The patients completed the double-
blind study were enrolled consecutively until the enrolments reached the targeted number of patient. By then, the enrolment was ended. LDA, low-
dose aspirin.
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20 mg compared with lansoprazole 15 mg, and the degree of 
increase with vonoprazan was dose dependent. In post hoc anal-
yses of the extension study, H. pylori status and ulcer incidence 
among patients with serum gastrin level of over 500 pg/mL were 
comparable in all groups (see Appendix table 1 in the online 
Supplementary file 1).
Pepsinogen I and II concentrations increased at week 4 
in all treatment groups and remained stable through week 
52, as did the pepsinogen I/II ratio (figure 3). The increase 
of pepsinogen I and II is observed by lansoprazole as well, 
though the increase was smaller compared with vonoprazan 
treatments.
Table 1 Patient characteristics at baseline
Characteristic lansoprazole 15 mg (n=217) Vonoprazan 10 mg (n=202) Vonoprazan 20 mg (n=202)
Age, mean (SD) years 68.3 (9.06) 68.9 (8.02) 69.1 (7.18)
Gender, n (%)
  Male 178 (82.0) 166 (82.2) 163 (80.7)
  Female 39 (18.0) 36 (17.8) 39 (19.3)
BMI, mean (SD) kg/m2 24.48 (3.234) 24.40 (3.395) 23.68 (3.334)
Current or ex-smoker, n (%) 168 (77.4) 158 (78.2) 161 (79.7)
Alcohol consumption, n (%) 120 (55.3) 128 (63.4) 118 (58.4)
Underlying disease, n (%)
  Ischaemic heart disease 136 (62.7) 121 (59.9) 119 (58.9)
  Ischaemic cerebrovascular disorder 71 (32.7) 76 (37.6) 80 (39.6)
  Other 39 (18.0) 44 (21.8) 49 (24.3)
Helicobacter pylori status, n (%)
  Negative 127 (59.6) 118 (58.4) 119 (59.2)
  Positive 86 (40.4) 84 (41.6) 82 (40.8)
CYP2C19 polymorphism, n (%)
  Extensive metaboliser 187 (87.0) 163 (81.5) 160 (79.6)
  Poor metaboliser 28 (13.0) 37 (18.5) 41 (20.4)
Dosage of long-term LDA, n (%)
100 mg/day (or 81 mg/day aspirin/dialuminate) 209 (96.3) 194 (96.0) 193 (95.5)
  200 mg/day (or 162 mg/day aspirin/dialuminate) 8 (3.7) 8 (4.0) 9 (4.5)
Other antithrombotic drug*, n (%) 91 (41.9) 85 (42.1) 81 (40.1)
*Clopidogrel, warfarin, ticlopidine or others (additional analysis).
BMI, body mass index; CYP, cytochrome P450; LDA, low-dose aspirin.
Table 2 Incidence of recurrent peptic ulcer during 24 weeks of treatment in subgroups stratified by baseline characteristics
Characteristic
recurrence rate, % (n/n)
lansoprazole 15 mg Vonoprazan 10 mg Vonoprazan 20 mg
Helicobacter pylori status
  Negative 3.3 (4/123) 0.9 (1/114) 2.6 (3/116)
  Positive 2.3 (2/86) 0 (0/83) 0 (0/79)
CYP2C19 genotype
  Extensive metaboliser 2.7 (5/184) 0.6 (1/162) 1.3 (2/155)
  Poor metaboliser 3.6 (1/28) 0 (0/35) 2.4 (1/41)
Age
  <65 years 1.4 (1/69) 1.9 (1/53) 0 (0/50)
  ≥65 to <75 years 2.2 (2/90) 0 (0/91) 2.0 (2/99)
  ≥75 years 5.6 (3/54) 0 (0/53) 2.1 (1/47)
Smoking status
  Current or ex-smoker 1.8 (3/165) 0.6 (1/155) 1.9 (3/155)
  Never smoker 6.3 (3/48) 0 (0/42) 0 (0/41)
Alcohol consumption status
  Drinker 1.7 (2/119) 0.8 (1/126) 0.9 (1/117)
  Never drink 4.3 (4/94) 0 (0/71) 2.5 (2/79)
Oral antithrombotic drug*
  Yes 2.2 (2/91) 0 (0/83) 2.5 (2/79)
  No 3.3 (4/122) 0.9 (1/114) 0.9 (1/117)
*Additional analysis.
CYP, cytochrome P450.
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DIsCussIOn
This is the first study to assess the safety and efficacy of vono-
prazan for the prevention of peptic ulcer recurrence in patients 
receiving long-term LDA therapy. The double blind, randomised 
phase of the study demonstrated that vonoprazan 10 mg and 
20 mg were non-inferior to lansoprazole 15 mg in the preven-
tion of peptic ulcer recurrence over 24 weeks of treatment. The 
protective effect of vonoprazan was long lasting, as demon-
strated by the low cumulative incidence of both peptic ulcer 
recurrence and bleeding of the stomach/duodenum during the 
long-term (up to 2 years) extension study, and there were rela-
tively few safety concerns associated with vonoprazan. Although 
concern has previously been noted that long-term PPI adminis-
tration may cause decreased absorption of vitamin B12, calcium 
and/or magnesium, in our study there was no fluctuation in the 
serum levels during the prolonged study period. Together, these 
results indicate that vonoprazan is an effective alternative treat-
ment to PPIs for secondary prevention of peptic ulcer in patients 
who require LDA therapy for cardiovascular or cerebrovascular 
protection.
Patients enrolled in this study had a history of peptic ulcer 
and were receiving long-term LDA therapy to prevent the 
formation of thrombi; therefore, the patients were at high risk 
of ulcer recurrence. However, the proportions of patients with 
recurrent peptic ulcer during 24 weeks of treatment were low 
in all three groups (2.8%, 0.5% and 1.5% in the lansopra-
zole 15 mg, vonoprazan 10 mg and vonoprazan 20 mg groups, 
respectively), reflecting the efficacy of all three treatment regi-
mens. Non-inferiority of each vonoprazan dose to lansoprazole 
was verified; however, despite the lower rates of peptic ulcer 
Figure 2 Kaplan-Meier estimates of the cumulative incidence of (A) peptic ulcer recurrence and (B) bleeding in the stomach or duodenum in 
patients treated with lansoprazole 15 mg (dotted line), vonoprazan 10 mg (solid line) or vonoprazan 20 mg (thick solid line). The numbers of patients 
at risk for each treatment group are shown in table 1.
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recurrence in patients receiving vonoprazan, superiority over 
lansoprazole could not be demonstrated in the 24-week study. 
During long-term treatment, however, vonoprazan was observed 
to have lower rates of ulcer recurrence compared with lansopra-
zole. In addition, both doses of vonoprazan were significantly 
more effective than lansoprazole at preventing bleeding of the 
stomach/duodenum during long-term treatment. The results 
achieved with vonoprazan compare favourably with those 
reported previously for lansoprazole 15 mg8 and are in line with 
those reported for esomeprazole 20 mg20 and rabeprazole 5 mg 
and 10 mg21 in similarly designed studies conducted in similar 
patent populations.
In addition to oral administration of non-steroidal anti-in-
flammatory drugs (NSAIDs), confirmed or possible risk factors 
for ulcer occurrence include history of ulcer, advanced age, H. 
pylori infection, smoking, alcohol intake and concomitant use of 
anticoagulant therapy.2 Patients enrolled in the current study had 
a confirmed history of ulcer and potentially one or more addi-
tional risk factors. For example, the mean age of enrolled patients 
was approximately 69 years and nearly 80% were current or 
ex-smokers. Approximately, 40% of patients were positive for 
H. pylori and about 40% were receiving other antithrombotic 
drug therapy in addition to LDA. These risk factors could be 
attributed to the study design using PPI, which is expected to 
have high efficacy, as an active comparator for the study, unlike 
previous studies conducted using mucosal-protective drugs.8 20 21 
Despite these risk factors, analysis of the primary endpoint in 
patient subgroups defined by baseline characteristics revealed a 
consistent effect of vonoprazan on ulcer recurrence, with recur-
rence rates for vonoprazan 10 mg and 20 mg similar to or lower 
than those for lansoprazole 15 mg within each subgroup. There 
were studies reporting the GI bleeding incidence rise in propor-
tion to the numbers of antithrombotics prescribed.22 23 There-
fore, it is of note that in this study, stomach/duodenal bleeding 
incidence in lansoprazole 15 mg group after 24 weeks was 1.7% 
without using antithrombotics with LDA alone, but was 4.4% 
with additional antithrombotics use, and increasing tendency 
was observed in post hoc analyses of the double-blind study 
although no clinically significant bleeding occurred in the endo-
scopically confirmed cases. Our study was not designed to eval-
uate clinically important GI bleeding, therefore these results 
should be interpreted with caution. However, vonoprazan may 
offer some advantage on bleeding, such as GI bleeding, which is 
a harder GI endpoint, considering the significant reduction in 
endoscopic stigmata of bleeding.
Vonoprazan was well tolerated in the study. During long-term 
treatment, the safety profiles of the 10 mg and 20 mg doses were 
similar to that of lansoprazole 15 mg. Recent systematic reviews 
and meta-analyses have suggested a relationship between PPI use 
and increased risk of fracture24 and/or gastroenteritis infections 
induced by C. difficile.25 26 In the current study, the incidence of 
fracture was similar in all three treatment groups and no cases of 
gastroenteritis infections due to C. difficile were observed.
Long-term use of PPIs has also been associated with a poten-
tially increased risk of GI cancer, possibly related to hypergas-
trinaemia, although the relationship is questionable.27–30 The 
two patients in 20 mg group who were reported with carcinoma 
were identified by the Central Evaluation Committee for being 
diagnosed retrospectively with cancer before the study drug 
administration. In the study of vonoprazan administered during 
Table 3 Summary of treatment-emergent adverse events (TEAEs) during both the double-blind and extension studies
lansoprazole 15 mg (n=217) Vonoprazan 10 mg (n=202) Vonoprazan 20 mg (n=202)
events, n Patients, n (%) events, n Patients, n (%) events, n Patients, n (%)
Summary of TEAEs
  Any adverse event 716 184 (84.8) 650 177 (87.6) 637 176 (87.1)
  Causal relationship to study drug could not be eliminated 73 53 (24.4) 45 33 (16.3) 55 39 (19.3)
  Leading to study discontinuation 21 20 (9.2) 19 16 (7.9) 15 15 (7.4)
Serious adverse events (including deaths) 39 32 (14.7) 43 33 (16.3) 38 32 (15.8)
  Causal relationship to study drug could not be eliminated 3 3 (1.4) 5 4 (2.0) 4 4 (2.0)
Deaths 0 0 1 1 (0.5) 0 0
TEAEs of special interest
  Fracture* 3 3 (1.4%) 7 7 (3.5%) 5 5 (2.5%)
  Clostridium difficile infection† 0 0 0 0 0 0
  GI carcinoma‡ 1 1 (0.5%) 3 3 (1.5%) 6 6 (3.0%)
TEAEs reported by ≥5% of patients in any group
  Nasopharyngitis 68 (31.3) 60 (29.7) 63 (31.2)
  Diarrhoea 26 (12.0) 15 (7.4) 19 (9.4)
  Constipation 16 (7.4) 13 (6.4) 17 (8.4)
  Upper respiratory tract inflammation 10 (4.6) 12 (5.9) 13 (6.4)
  Fall 13 (6.0) 11 (5.4) 8 (4.0)
  Back pain 5 (2.3) 8 (4.0) 16 (7.9)
  Elevated creatine phosphokinase 10 (4.6) 8 (4.0) 11 (5.4)
  Contusion 14 (6.5) 7 (3.5) 7 (3.5)
  Hypertension 7 (3.2) 8 (4.0) 10 (5.0)
  Gastroenteritis 6 (2.8) 10 (5.0) 8 (4.0)
  Eczema 7 (3.2) 10 (5.0) 5 (2.5)
*Preferred terms: foot fracture, spinal compression fracture, femur fracture, hand fracture, humerus fracture, lower limb fracture, radius fracture, rib fracture, spinal fracture.
†Preferred terms: Clostridia infections, C. difficile bacillaemia, Clostridium colitis, C. difficile colitis, C. difficile infection, C. difficile sepsis, Clostridia test positive, Clostridia 
enterogastritis, pseudomembranous colitis.
‡Preferred terms: gastric cancer, oesophageal carcinoma, adenocarcinoma gastric.
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the long-term NSAID therapy, we have identified no new safety 
issue.31
As expected from previous vonoprazan studies, serum gastrin 
concentrations were higher with vonoprazan (both doses) 
compared with lansoprazole; however, no patients discon-
tinued because of hypergastrinaemia. Similar changes in gastrin, 
pepsinogen I and II were reported in patients with GORD when 
treated with either vonoprazan or lansoprazole.32 The mech-
anism of such increase in these parameters are still unknown; 
however, other PPIs shown similar effects.33
Concomitant use of PPIs and clopidogrel has been reported to 
possibly reduce the inhibitory action of clopidogrel on platelet 
aggregation.34 35 In the Kumamoto Intervention Conference 
Study, the cumulative incidence of cardiovascular events during 
6 months of treatment was about 1.3% (value estimated from 
the published figure) in both the PPI group and non-PPI group 
in Japanese patients receiving dual therapy with LDA and clopi-
dogrel or ticlopidine.36 In the current study, no cardiovascular 
event developed in 120 patients who concomitantly received 
clopidogrel and LDA.
These results are strengthened by the randomised, double-blind 
design of the 24-week phase, long follow-up in the parallel-group 
extension phase and low discontinuation rate in both phases. 
Further, the non-inferiority design of the 24-week phase included 
a conservative non-inferiority margin and a reliable active control 
event rate (ie, 2.8% ulcer recurrence rate in the lansoprazole 
group). However, the study is somewhat limited by the variable 
duration of treatment in the extension phase. Also, since the inci-
dence of lower GI adverse events, such as diarrhoea, can be due to 
a change in intestinal flora, another limitation may be that we did 
not collect any data on intestinal flora.
In conclusion, vonoprazan at doses of 10 mg and 20 mg once 
daily was non-inferior to lansoprazole 15 mg for the prevention 
of ulcer recurrence in Japanese patients with a confirmed history 
of peptic ulcers who required LDA therapy for cardiovascular or 
cerebrovascular protection. Vonoprazan was well tolerated and its 
preventive effect on ulcer recurrence endured with long-term use. 
In addition, vonoprazan 10 mg and 20 mg showed a significantly 
greater preventive effect compared with lansoprazole 15 mg on 
the development of bleeding in the stomach or duodenum. Vono-
prazan therefore appears to be a useful alternative to lansoprazole 
for secondary prevention of LDA-associated peptic ulcers at the 
recommended clinical daily dose of vonoprazan of 10 mg (no ther-
apeutic advantage in 20 mg dose of vonoprazan over 10 mg was 
shown).
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